Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

gain over time. To date, the only highly effective treatment option is surgical and limited to the minority of patients who have advanced to the most severe forms of obesity," said Steven R. Smith, M.D., professor and assistant director of clinical research at the Pennington Biomedical Research Center. "Providing the over 80 million overweight and obese Americans who have a BMI less than 35 kg/m2 with safe treatment options that offer compelling weight loss would be a significant advancement in obesity drug development."

The combination therapy was well tolerated, and no cardiovascular or neuropsychiatric (such as anxiety or depression) safety signals were observed. Consistent with previous clinical experience, the most common side effects seen with pramlintide/metreleptin combination treatment were injection site adverse events and nausea, which were mostly mild or moderate and transient in nature.

"These findings provide us with valuable data that will inform our clinical and product development strategy moving forward," said Christian Weyer, M.D., vice president, corporate development, diabetes and obesity at Amylin Pharmaceuticals. "Our integrated neurohormonal approach to obesity provides a broad research and development platform that has the potential to yield transformational therapies that address a range of unmet patient needs across the various classes of obesity."

Study Details

This Phase 2, 28-week, double-blind, placebo-controlled multi-center study randomized 608 obese or overweight patients with a BMI ranging from 27-45 kg/m2. Patients were well-distributed across this BMI range, with approximately 40% of patients at a starting BMI less than 35 kg/m2. Following a one-week placebo lead-in period, study subjects were randomized in a balanced fashion to receive twice-daily therapy with one of the following eight treatment regimens: 1) placebo/placebo; 2) pramlintide 360 mcg/placebo; 3)
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Jan. 14, 2014   Kinaxis ®, provider of RapidResponse ... sales and operations planning ( S&OP ) service, is proud ... , which will be held at the Hilton San Diego ... Kinaxis customer Elisabeth Kaszas , Director of Supply Chain ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Encorium Group, Inc. (Nasdaq:  ENCO), (the "Company"), ... conducting studies in over 30 countries for many ... today announced that, on October 20, 2010, it ... (the "Panel") has determined to delist the Company,s ...
... Inc (OTC: OMCM.OB) today announced that it ranked number ... 500 of the fastest growing technology, media, telecommunications, life ... are based on the percentage of fiscal year revenue ... percent during this period. OmniComm,s CEO, Cornelis ...
... even harder in recent years the influenza A virus has ... Reporting their findings in the journal Science, researchers ... not, and how future treatments can defeat the nasty bug no ... are no longer recommended by the CDC for use against flu. ...
Cached Biology Technology:Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 2Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 3Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors 4OmniComm Ranks Number 220 on Deloitte's 2010 Technology Fast 500 for Fastest Growing Companies in North America 2OmniComm Ranks Number 220 on Deloitte's 2010 Technology Fast 500 for Fastest Growing Companies in North America 3Putting a bull's-eye on the flu: Detailing influenza's structure for drug targeting 2
(Date:7/10/2014)... from The University of Texas Health Science Center at ... (IYG), a health education program designed to delay sexual ... dating violence behaviors among minority youth. , According to ... of high school youth are victims of physical dating ... percent are victims of emotional dating violence. Previous studies ...
(Date:7/10/2014)... children and teens living with a cardiac pacemaker, a ... quality of life, reports a study in the July ... , the official journal of the Society for ... published by Lippincott Williams & Wilkins , a ... may function as a protective factor against lower health-related ...
(Date:7/10/2014)... National Cancer Research Centre (CNIO) Macromolecular Crystallography Group ... protein called BuD to DNA in order to ... the researcher who led the study, says the ... the instructions contained in the genome to treat ... study is published in the journal Acta ...
Breaking Biology News(10 mins):It's Your Game ... Keep It Real reduces dating violence among minority youth 2For children with pacemakers, 'self-competence' affects quality of life 2CNIO scientists develop technology to redirect proteins towards specific areas of the genome 2
... Munich have developed a new method for visualizing material ... team led by Bert Nickel has, for the first ... organic thin-film solar cells using laser light for localized ... the scientific journal " Advanced Materials ". "We have ...
... has published research this week in a leading science ... they were raised rather than that likely to maximize ... of habitat selection theory. The paper is published ... on June 26 and includes co-authors Michael Palmer, ...
... significantly challenged as production levels fall due to ... the industry,s competitiveness are being sought. The South ... Resources and Energy (DMITRE) has invited VTT Technical ... study that identifies potential routes by which the ...
Cached Biology News:Organic electronics: Imaging defects in solar cells 2Bioeconomy as a solution for South Australia's declining forest industry 2Bioeconomy as a solution for South Australia's declining forest industry 3
...
... The Varian 500-MS LC Ion Trap ... high-throughput LC/MS analysis where sensitivity, reliability ... 500-MS provides a robust platform for ... mass resolution, and mass stability reflect ...
... modular benchtop fume hood ventilates ... safe indoor release of exhaust. ... organic contaminants. Configurations are available ... options include final HEPA filter, ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Biology Products: